PRE Prenetics Global Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1876431 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY40.8%
TTM net income YoY26.2%
TTM EPS YoY33.5%
Revenue 3-yr CAGR34.7%
Net income 3-yr CAGR—
Margins
Gross margin50.3%
Operating margin-157.2%
Net margin-151.2%
FCF margin-97.6%
EBITDA margin—
Returns
ROE-24.6%
ROA-19.8%
ROIC (approx.)-27.3%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets19.8%
Debt / equity0.00x
Current ratio2.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $30.62M | $21.74M | $13.16M | $12.53M | $65.18M |
| Cost of revenue | $15.22M | $12.91M | $9.55M | $8.93M | $38.83M |
| Gross profit | $15.40M | $8.83M | $3.62M | $3.60M | $26.34M |
| R&D expense | $10.92M | $11.66M | $5.99M | $6.39M | $2.78M |
| Operating income | -$48.14M | -$51.91M | -$66.02M | -$56.66M | -$995,126 |
| Interest expense | — | — | $4.20M | $5.24M | $59,567 |
| Pretax income | -$57.70M | -$56.67M | -$225.82M | -$216.55M | -$3.90M |
| Income tax | -$7.87M | -$269,000 | -$245,000 | $2.57M | -$1.94M |
| Net income | -$46.30M | -$62.72M | -$190.45M | -$174.01M | -$1.94M |
| EPS (basic) | -3.71 | -5.58 | -37.57 | -178.81 | -0.15 |
| EPS (diluted) | -3.71 | -5.58 | -37.57 | -178.81 | -0.15 |
| Weighted avg. shares (diluted) | 12.49M | 11.25M | 5.07M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $52.25M | $45.71M | $146.66M | $35.29M | $14.49M |
| Short-term investments | $0 | $16.00M | $19.92M | — | — |
| Receivables | $16.77M | $17.66M | $53.16M | $54.86M | — |
| Inventory | $6.57M | $3.13M | $4.53M | $6.83M | — |
| Current assets | $86.15M | $93.66M | $241.81M | $106.89M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $7.81M | $5.78M | $13.10M | $13.04M | — |
| Goodwill | $37.36M | $29.17M | $33.80M | $3.98M | $3.99M |
| Intangibles | $11.57M | $13.43M | $14.79M | $23.83M | — |
| Total assets | $213.57M | $254.17M | $312.13M | $148.51M | — |
| Current liabilities | $36.55M | $39.48M | $57.20M | $58.74M | — |
| Total liabilities | $42.23M | $44.01M | $68.67M | $549.40M | — |
| Shareholders' equity | $170.39M | $206.36M | $237.06M | -$400.81M | $31.01M |
| Shares outstanding | 12.98M | 12.21M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$28.87M | -$13.77M | $14.52M | $13.42M | -$2.88M |
| Capital expenditure | $1.01M | $345,000 | $4.95M | $8.55M | $2.86M |
| Free cash flow | -$29.88M | -$14.11M | $9.57M | $4.87M | -$5.74M |
| Investing cash flow | $38.54M | -$82.95M | -$46.15M | -$22.02M | -$5.97M |
| Financing cash flow | -$3.34M | -$4.70M | $143.32M | $29.32M | $11.84M |
| Stock-based compensation | $7.85M | $10.59M | $31.58M | $22.49M | $1.62M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.